Literature DB >> 1363894

Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies.

S M McLachlan1, R Bahn, B Rapoport.   

Abstract

Autoantibodies to the three major thyroid autoantigens, the TSH-receptor (TSH-R), thyroid peroxidase (TPO) and thyroglobulin (TG), have been investigated in 63 Graves' patients with severe endocrine ophthalmopathy. In agreement with other studies, TSH-R antibodies were detectable in 88% of patients and dominated the autoantibody spectrum. TPO antibodies were detectable in 60% of patients and TG antibodies in only 25% of patients. The prevalences, as well as the amounts, of all three thyroid autoantibodies were not significantly different from the values in 51 Graves' patients without clinically significant ophthalmopathy. However, in the subgroup of patients with TG antibodies, the ophthalmopathy patients displayed a shift towards IgG4 TG antibodies. Furthermore, in the same TG antibody positive subgroup, the amount of TSH-R antibody was significantly higher in the ophthalmopathy patients than in Graves' patients without ophthalmopathy. These qualitative differences in thyroid autoantibodies in patients with and without ophthalmopathy raise the possibility that further qualitative differences, such as thyroid autoantibody epitopes, may exist in patients with ophthalmopathy. Our observations, combined with recent evidence for the presence of TSH-R specific mRNA in retro-orbital tissue, suggest that it may be premature to dismiss the potential pathogenetic or diagnostic value of thyroid autoantibodies, particularly TSH-R antibodies, in Graves' ophthalmopathy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363894     DOI: 10.3109/08916939209083133

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

Review 1.  Pharmacological treatments for thyroid eye disease.

Authors:  Sara P Modjtahedi; Bobeck S Modjtahedi; Ahmad M Mansury; Dinesh Selva; Raymond S Douglas; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.

Authors:  K Kazuo; T Fujikado; G Ohmi; J Hosohata; Y Tano
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 3.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

4.  Serum immunoglobulin G4 levels and Graves' disease phenotype.

Authors:  Carmen Sorina Martin; Anca Elena Sirbu; Minodora Andreea Betivoiu; Suzana Florea; Carmen Gabriela Barbu; Simona Vasilica Fica
Journal:  Endocrine       Date:  2016-11-07       Impact factor: 3.633

5.  IgG subclass distribution of thyroglobulin antibodies in patients with thyroid disease.

Authors:  P Caturegli; R C Kuppers; S Mariotti; C L Burek; A Pinchera; P W Ladenson; N R Rose
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

6.  Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction.

Authors:  A Barsouk; K A Peele; J Kiljanski; C Stolarski; V Nebes; J S Kennerdell; R Volpe; J R Wall
Journal:  J Endocrinol Invest       Date:  1996-06       Impact factor: 4.256

7.  Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves' ophthalmopathy.

Authors:  Aleksander Kuś; Konrad Szymański; Beata Jurecka-Lubieniecka; Edyta Pawlak-Adamska; Dorota Kula; Piotr Miśkiewicz; Marek Bolanowski; Rafał Płoski; Artur Bossowski; Jacek Daroszewski; Barbara Jarząb; Tomasz Bednarczuk
Journal:  J Hum Genet       Date:  2016-11-10       Impact factor: 3.172

8.  Thyroid peroxidase antibody positivity and triiodothyronine levels are associated with pediatric Graves' ophthalmopathy.

Authors:  Jung Hyun Lee; So Hyun Park; Dae Gyun Koh; Byung Kyu Suh
Journal:  World J Pediatr       Date:  2014-03-25       Impact factor: 2.764

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.